SCHEMBL24512262

SCHEMBL24512262

Cc1ccc(Br)cc1S(=O)(=O)N1CCOCC1

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
MAPT P10636 2/20 0.65
ALDH1A1 P00352 6/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
CNR2 P34972 4/20 0.57
KMT2A Q03164 1/20 0.57
HTT P42858 1/20 0.57
BRD4 O60885 1/20 0.56
BRD2 P25440 1/20 0.56
BRD3 Q15059 1/20 0.56
CNR1 P21554 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29717131 1.00 LMNA (0.65) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2927007 0.88 ALDH1A1 (0.66) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL15052643 0.84 ALDH1A1 (0.67) LMNAALDH1A1SMN1; SMN2L3MBTL1CNR2
SCHEMBL22433209 0.84 ALDH1A1 (0.69) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL23294420 0.83 KMT2A (0.60) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2080681 0.82 TP53 (0.65) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL1592716 0.82 ALDH1A1 (0.61) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL16345591 0.82 LMNA (0.54) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL9319918 0.82 ALDH1A1 (0.61) LMNAMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL841667 0.81 LMNA (0.52) LMNAMAPTALDH1A1SMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117915903-A Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof 佛罗里达大学研究基金会公司 2024-04-19 CN disclosed
WO-2022125989-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS SCRIPPS RESEARCH INSTITUTE, THE (US) 2022-06-16 WO disclosed